IN THE CLAIMS

Please amend the claims as follows:

1. (Twice Amended) A compound which is an antagonist of a G protein-coupled receptor, which has no agonist activity, and which has a cyclic or constrained acyclic structure adapted to provide a framework of approximate dimensions as set out in Structure I:

Structure I



where the numerals refer to distances between C_α carbons of amino acids or their analogues or derivatives, and A, B, C and D are not necessarily on adjacent amino acids, or analogues or derivatives thereof; and

where the critical amino acid side chains are designated by A, B, C and D, where

A is any common or uncommon, basic, charged amino acid side chain which serves to position a positively charged group in this position;

B is any common or uncommon, aromatic amino acid side chain which serves to position an aromatic side-chain in this position;

C is any common or uncommon, hydrophobic amino acid side chain which serves to position any alkyl, aromatic or other group in this position;

D is any common or uncommon, aromatic amino acid which serves to position an aromatic side-chain in this position, and has the structure:

E1 Conclude



where Z is indole, indole methyl, benzyl, benzene, naphthyl, naphthyl methyl, or a derivative thereof; and

R^1 is H or an alkyl, aromatic, acyl or aromatic-acyl group.

E2

5. (Twice Amended) An antagonist according to Claim 1, which is a constrained acyclic compound, comprising a type II β-turn.

E3

8. (Twice Amended) An antagonist according to Claim 1, of formula

Ac-Phe-[Lys-Pro-(dCha)-Trp-Arg] or

Ac-Phe-[Orn-Pro-(dCha)-Trp-Arg].

E4

13. (Twice Amended) An antagonist according to Claim 10, selected from the group consisting of AcF-[KpdChaWR], AcF-[OPdChaWR], F-[XPdChaWR], F-[XPdChaWR], F-[X^2PdChaWR], F-[X^2PdChaWR], AcF-[OPdChaWR], AcF-[OPdChaWR], [FWPdChaWR], AcF-[KMdChaWR], AcF-[KKdChaWR], AcF-[XPdChaWR], AcF-[X^2PdChaWR], AcKF-[OPdChaWR], F-[OPdChaWR], F-[KPdChaWR], F-[OPdChaWR] and F-[KPdChaWR], wherein X is (CH_2)-NH_2 and X^2 is $(CH_2)_2$-NH_2.

14. (Twice Amended) An antagonist according to Claim 10, in which n is 2 or 3.

E5

21. (Twice Amended) A method of treatment of a pathological condition mediated by a G - protein-coupled receptor, comprising the step of administering an effective amount of a